February 12, 2025 (IRVINE, Calif.) – Johnson & Johnson MedTech has launched the CEREGLIDE™ 92 Catheter System, a next‑generation neurovascular catheter designed to aid physicians in treating acute ischemic stroke and related cerebrovascular conditions. The system is now commercially available in the United States, marking a significant step forward in stroke intervention technology.
“Johnson & Johnson MedTech is continuing to innovate to help address the access challenges physicians face during mechanical thrombectomy procedures with the launch of CEREGLIDE™ 92,” said Mark Dickinson, Worldwide President of Neurovascular at Johnson & Johnson MedTech.
The CEREGLIDE 92 Catheter System is designed for use in the neurovascular system to facilitate the insertion and guidance of interventional devices during mechanical thrombectomy procedures — a common and critical treatment for ischemic strokes, which make up approximately 85% of all strokes worldwide.
Key Features:
- Large .092″ Inner Diameter: Allows physicians to achieve broader distal access in the brain’s blood vessels.
- INNERGLIDE™ 9 Delivery Aid: Co‑packaged with the catheter to improve insertion and device support.
- Enhanced Trackability: Includes TruCourse™ Technology to increase flexibility and improve navigation through complex cerebral anatomy.
- Full Visibility: BRITE‑LINE™ Technology enables complete catheter visibility under fluoroscopy for precise procedural control.
- Support for Complex Procedures: The larger lumen also supports other neurovascular tools used in treating aneurysms and hemorrhagic complications.
The CEREGLIDE 92 system joins Johnson & Johnson MedTech’s growing portfolio of stroke‑focused tools, including CEREGLIDE™ 71 and other Stroke Solutions, aimed at improving procedural success and patient outcomes in challenging neurovascular interventions.
